Ben Cohen, MD
Retina Specialist · New York, NYNPI 1083608186
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,125 of the $5,460 with a category attached, or 75.6%. It is spread thinly across 23 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations.
Across 111 payments — averaging $49.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$1K
- Johnson & Johnson$654
- Alcon$591
- AbbVie$406
- Johnson & Johnson Surgical Vision, Inc.$351
- Alimera Sciences, Inc.$275
- plus $2K from 17 others
Across 128 payments — averaging $729.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$93K
What the payments were for
- Consulting fees$1,30024%
- Food & beverage$4,12576%
- Education$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 1 | $1,300 |
| Johnson & Johnson | 8 | $654 |
| Alcon | 29 | $591 |
| AbbVie(2 entities) | 14 | $406 |
| Johnson & Johnson Surgical Vision, Inc. | 12 | $351 |
| Alimera Sciences, Inc. | 2 | $275 |
| Regeneron Healthcare Solutions, Inc. | 10 | $251 |
| Alphatec Spine, Inc | 1 | $247 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $234 |
| Rxsight Inc | 2 | $196 |
| Novartis | 4 | $175 |
| Genentech, Inc. | 1 | $150 |
| Bausch & Lomb Americas Inc. | 7 | $144 |
| Apellis Pharmaceuticals, Inc. | 2 | $115 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $89 |
| Iridex Corporation | 1 | $78 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 2 | $47 |
| UCB, Inc. | 3 | $42 |
| Astellas Pharma US Inc | 1 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Glaukos Corporation | 1 | $21 |
| Dutch Ophthalmic, USA | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FORUM$1,300
- FORUM Glaucoma Workplace$1,300
- Humphrey HFA$1,300
- IOLMaster 700$1,300
- Tremfya$386
- Iluvien$275
- Entyvio$234
- SUSVIMO$150
- Centurion$146
- STELARA$139
- BEOVU$125
How this compares
$5,460 in reported general payments places this provider in the 70th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 36 | $30,862 |
| LumiganBimatoprost | 78 | $28,238 |
| Prednisolone Acetate | 440 | $18,064 |
| CombiganBrimonidine Tartrate/Timolol | 47 | $17,137 |
| RestasisCyclosporine | 25 | $16,800 |
| Ketorolac Tromethamine | 608 | $14,857 |
| Brimonidine Tartrate | 229 | $11,901 |
| MieboPerfluorohexyloctane/Pf | 11 | $9,565 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 663 | $8,710 |
| RhopressaNetarsudil Mesylate | 11 | $7,373 |
| Ciprofloxacin Hcl | 309 | $4,521 |
| Tobradex StTobramycin/Dexamethasone | 18 | $4,221 |
| ZyletTobramycin/Lotepred Etab | 11 | $3,995 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 17 | $3,813 |
| Latanoprost | 592 | $3,558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis | $406 | $62,174150 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $144 | $40,42647 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCZylet, Loteprednol Etabonate | $89 | $5,52024 claims |
| AlconSimbrinza | $591 | $3,81317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 99 retina specialist providers in New York.
Other retina specialist in New York
- Szilard KissNew York$195K
- Donald D'amicoNew York$109K
- Gareth LemaNew York$11K
- Megan Ridley LaneNew York$11K
- Carl WilkinsNew York$9K
- Gennady LandaNew York$7K
- Joseph TsengNew York$6K
- Alan SheymanNew York$4K
- Steven AgemyNew York$3K
- Louis AngiolettiNew York$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.